BRIEF — FDA Approves Inluriyo In Combination With Verzenio For ER+, HER2 —, ESR1 — Mutated Advanced Breast Cancer
Sept 18 (Reuters) — Eli Lilly and Company: U.s. Fda Approves Inluriyo (Imlunestrant) In Combination With Verzenio (Abemaciclib) For Adults With Er+, Her2-, Esr1-mutated Advanced Or Metastatic Breast Cancer Eli Lilly - Inluriyo With Verzenio Now Available In The United States Source text:... Further company coverage: LLY.N ((( Reuters.Briefs@thomsonreuters.com;));)
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.